The content on this site is intended for healthcare professionals only
Prof Giancarlo Agenelli speaks to ecancer at the International Aspirin Foundation Scientific Conference 2019 in Rome about the effectiveness of combining antiplatelet and anticoagulant strategies in high-risk patients.
He describes data from a clinical trial which evaluated the combination of low-dose aspirin and low-dose rivaroxaban.
Prof Agnelli also discusses additional measures that could reduce adverse events such as cardiovascular death and death and whether these should be incorporated into clinical guidelines.
Read more on the highlights from the 2019 International Aspirin Foundation Scientific Conference here.
Treatment management of favourable risk and very favourable risk patients
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective
Recommendations and guidance for people living with and beyond breast cancer and colorectal cancer
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Durable responses in aRCC, how do we optimise treatment?
Perspectives on advance care planning for advanced cancer in the Philippines
